Related search

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

P1.01-35 Tumor Volume Analysis in ALK-Rearranged NSCLC Treated With Crizotinib: Identifying an Early Marker for Clinical Outcome

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Crizotinib: A Multicenter Cohort Retrospective Study.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

PIG3 Promotes NSCLC Cell Mitotic Progression and Is Associated With Poor Prognosis of NSCLC Patients

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Lower Blood Calcium Associates With Unfavorable Prognosis and Predicts for Bone Metastasis in NSCLC

PLoS ONE
Multidisciplinary
2012English

High LIFr Expression Stimulates Melanoma Cell Migration and Is Associated With Unfavorable Prognosis in Melanoma

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy